In this review:
Adjuvant olaparib elicits clinical benefit in BRAC1/2-mutated high-risk HER2– early disease
GeparNUEVO: benefit to neoadjuvant immunotherapy for early-stage TNBC
PALOMA-3 confirms survival benefit of palbociclib + fulvestrant in HR+/HER2– disease
MONALEESA-3: fulvestrant plus ribociclib for HR+/HER2- advanced disease
Platinum adjuvant chemotherapy inferior to capecitabine for residual invasive TNBC
ASCENT: sacituzumab govitecan beneficial for recurrent metastatic TNBC regardless of age
Sacituzumab govitecan superior to chemotherapy in second-line metastatic setting for TNBC
Screening carriers of ATM, CHEK2 and PALB2 pathogenic variants reduces risk of mortality
Please login below to download this issue (PDF)